

	Drug	Associated model parameter	Targets	Associated genomic alterations
1	OSI-906	k ERK,RSKp90	IGF1R	MYC->PDK1,SMAD2
2	OSI-906	k MEK,ERK	IGF1R	MYC->PDK1,SMAD2
3	BMS-345541	τ cJun	IKBKB	PARK2-IcJun; MYC->PDK1,SMAD2
4	HG-5-88-01	k IKK,ERK	EGFR	
5	OSI-906	τ RPS6	IGF1R	MYC->PDK1,SMAD2
6	BMS-345541	k EGFR,PI3K	IKBKB	PARK2-IcJun; MYC->PDK1,SMAD2
7	SB590885	τ IκBa	BRAF	
8	AZD6244	τ GSK3	MEK	
9	HG-5-88-01	k MEK,ERK	EGFR	
10	PD-0325901	k IKK,ERK	MEK	
11	HG-5-88-01	k ERK,RSKp90	EGFR	
12	BMS-754807	τ RPS6	IGF1R	MYC->PDK1,SMAD2
13	SB590885	k ERK,RPS6	BRAF	
14	(5Z)-7-Oxozeaenol	k IKK,TBK1	MAP3K7 (TAK1)	
15	BMS-345541	k PI3K,PAK1	IKBKB	PARK2-IcJun; MYC->PDK1,SMAD2
16	AZD6244	k IKK,ERK	MEK	
17	AZD6244	k RSKp90,GSK3	MEK	
18	(5Z)-7-Oxozeaenol	k TGFRb,SMAD2	MAP3K7 (TAK1)	
19	RDEA119	k IKK,ERK	MEK	
20	RDEA119	k TGFRb,SMAD2	MEK	
21	(5Z)-7-Oxozeaenol	k MP2K4,JNK	MAP3K7 (TAK1)	
22	Dabrafenib	k ERK,RPS6	BRAF	
23	THZ-2-102-1	τ cJun	CDK7->MEK,PAK1	MYC->PDK1,SMAD2
24	RDEA119	τ GSK3	MEK	
25	HG-5-88-01	k ERK,RPS6	EGFR	
26	SB590885	k RSKp90,GSK3	BRAF	
27	Afatinib	τ ERK	EGFR; ERBB2->EGFR,SHC1,PI3K,GRB2,PAK1	MYC->PDK1,SMAD2
28	(5Z)-7-Oxozeaenol	k PI3K,S6K	MAP3K7 (TAK1)	
29	Dabrafenib	k TGFRb,SMAD2	BRAF	
30	BMS-345541	τ mTOR	IKBKB	PARK2-IcJun; MYC->PDK1,SMAD2
31	BMS-345541	k EGFR,TGFRb	IKBKB	PARK2-IcJun; MYC->PDK1,SMAD2
32	PD-0325901	k ERK,RPS6	MEK	
33	BMS-345541	τ RPS6	IKBKB	PARK2-IcJun; MYC->PDK1,SMAD2
34	(5Z)-7-Oxozeaenol	τ EGFR	MAP3K7 (TAK1)	
35	PD-0325901	k AKT,GSK3	MEK	
36	CI-1040	k PI3K,S6K	MEK	
37	HG-5-88-01	k ERK,BRAF	EGFR	
38	(5Z)-7-Oxozeaenol	k TAK1,JNK	MAP3K7 (TAK1)	
39	Afatinib	τ RPS6	EGFR; ERBB2->EGFR,SHC1,PI3K,GRB2,PAK1	MYC->PDK1,SMAD2
40	PD-0325901	k PI3K,S6K	MEK	
41	Dabrafenib	k PI3K,AKT	BRAF	
42	BMS-345541	k EGF,EGFR	IKBKB	PARK2-IcJun; MYC->PDK1,SMAD2
43	Trametinib	k IKK,ERK	MEK	
44	RDEA119	k IKK,IκBa	MEK	
45	BMS-345541	k AKT,PAK1	IKBKB	PARK2-IcJun; MYC->PDK1,SMAD2
46	AZD6244	k AKT,GSK3	MEK	
47	AZD6244	τ mTOR	MEK	
48	SB590885	k ERK,BRAF	BRAF	
49	PD-0325901	τ IκBa	MEK	
50	Trametinib	k TGFRb,SMAD2	MEK	